Skip to content

AYTU BIOPHARMA, INC

AYTU · XNAS

CIK 1385818fmd_0DGD15AK1ME9Z7JXWA2A9RWZRQManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Mar 01, 2005 to Jun 30, 2026, 74 periods

Latest annual · FY2026

Millions
Total revenues
58
Gross profit
37
Operating income
(8)
Net income
(14)
Free cash flow
3

Latest quarter · Q4 FY2026

Millions
Total revenues
16
Gross profit
10
Operating income
(1)
Net income
(0)
Free cash flow
4

Daily close · AYTUIEX trades only

Jul 15, 2025 to Nov 09, 2026 · 250 sessions

1.81 USD

1.502.002.503.00Jul 15, 2025Feb 11, 2026Nov 09, 2026Vol

Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.

Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms

Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2023 to FY2026
-18.8%
Revenue, 5 yearsFY2021 to FY2026
-2.6%
Net income, 5 yearsFY2021 to FY2026
n/m

AYTU BIOPHARMA, INC (AYTU) financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2026FY2025ChangeSource
Revenue$57.6 million$66.4 million-13.3%10-K 2026-09-22 · proof
Gross profit$36.8 million$45.8 million-19.7%10-K 2026-09-22 · proof
Operating income-$8.3 million-$7.8 million10-K 2026-09-22 · proof
Net income-$14.3 million-$13.6 million10-K 2026-09-22 · proof
Cash from operating activities$3.3 million-$1.9 million10-K 2026-09-22 · proof
Free cash flow$3.3 million-$2.2 million10-K 2026-09-22 · proof
Total assets$105 million$124.2 million-15.4%10-K 2026-09-22 · proof
Total liabilities$69.7 million$105.2 million-33.7%10-K 2026-09-22 · proof
Cash and cash equivalents$26.3 million$31 million-15%10-K 2026-09-22 · proof
Total debt$11 million$12.8 million-14.1%10-K 2026-09-22 · proof
What was AYTU BIOPHARMA, INC (AYTU)'s revenue in fiscal 2026?
AYTU BIOPHARMA, INC (AYTU) reported revenue of $57.6 million for fiscal 2026 (the year ended Jun 30, 2026), against $66.4 million the year before (-13.3%). Source: the 10-K filed with the SEC on Sep 22, 2026. SEC
What was AYTU BIOPHARMA, INC (AYTU)'s gross profit in fiscal 2026?
AYTU BIOPHARMA, INC (AYTU) reported gross profit of $36.8 million for fiscal 2026 (the year ended Jun 30, 2026), against $45.8 million the year before (-19.7%). Source: the 10-K filed with the SEC on Sep 22, 2026. SEC
What was AYTU BIOPHARMA, INC (AYTU)'s operating income in fiscal 2026?
AYTU BIOPHARMA, INC (AYTU) reported operating income of -$8.3 million for fiscal 2026 (the year ended Jun 30, 2026), against -$7.8 million the year before. Source: the 10-K filed with the SEC on Sep 22, 2026. SEC
What was AYTU BIOPHARMA, INC (AYTU)'s net income in fiscal 2026?
AYTU BIOPHARMA, INC (AYTU) reported net income of -$14.3 million for fiscal 2026 (the year ended Jun 30, 2026), against -$13.6 million the year before. Source: the 10-K filed with the SEC on Sep 22, 2026. SEC
What was AYTU BIOPHARMA, INC (AYTU)'s cash from operating activities in fiscal 2026?
AYTU BIOPHARMA, INC (AYTU) reported cash from operating activities of $3.3 million for fiscal 2026 (the year ended Jun 30, 2026), against -$1.9 million the year before. Source: the 10-K filed with the SEC on Sep 22, 2026. SEC
What was AYTU BIOPHARMA, INC (AYTU)'s free cash flow in fiscal 2026?
AYTU BIOPHARMA, INC (AYTU) reported free cash flow of $3.3 million for fiscal 2026 (the year ended Jun 30, 2026), against -$2.2 million the year before. Source: the 10-K filed with the SEC on Sep 22, 2026. SEC
What are AYTU BIOPHARMA, INC (AYTU)'s total assets?
As of Jun 30, 2026, AYTU BIOPHARMA, INC (AYTU) reported total assets of $105 million, against $124.2 million a year earlier (-15.4%). Source: the 10-K filed with the SEC on Sep 22, 2026. SEC
What are AYTU BIOPHARMA, INC (AYTU)'s total liabilities?
As of Jun 30, 2026, AYTU BIOPHARMA, INC (AYTU) reported total liabilities of $69.7 million, against $105.2 million a year earlier (-33.7%). Source: the 10-K filed with the SEC on Sep 22, 2026. SEC
What are AYTU BIOPHARMA, INC (AYTU)'s cash and cash equivalents?
As of Jun 30, 2026, AYTU BIOPHARMA, INC (AYTU) reported cash and cash equivalents of $26.3 million, against $31 million a year earlier (-15%). Source: the 10-K filed with the SEC on Sep 22, 2026. SEC
What is AYTU BIOPHARMA, INC (AYTU)'s total debt?
As of Jun 30, 2026, AYTU BIOPHARMA, INC (AYTU) reported total debt of $11 million, against $12.8 million a year earlier (-14.1%). Source: the 10-K filed with the SEC on Sep 22, 2026. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:AYTU&period_type=annual&limit=5"

Information only, not investment advice.